Rubius Therapeutics Inc (RUBY)

NASDAQ
7.20
-0.10(-1.37%)
  • Volume:
    210,501
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    6.98 - 7.28

RUBY Overview

Prev. Close
7.3
Day's Range
6.98-7.28
Revenue
-
Open
7.09
52 wk Range
6.76-38.71
EPS
-2.12
Volume
210,501
Market Cap
638.05M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
439,503
P/E Ratio
-
Beta
2.35
1-Year Change
-23%
Shares Outstanding
89,865,777
Next Earnings Date
Mar 31, 2022
What is your sentiment on Rubius Therapeutics Inc?
or
Vote to see community's results!

Rubius Therapeutics Inc Company Profile

Employees
268

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellStrong SellStrong SellStrong Sell
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Is it gonna be EntreMed number 2?
    0
    • Looking for additional insights into their pipelina?
      1
      • Ruby has anazing technolgy in approaching Cancer with a grear Board and officers. Could be a big winner
        1
        • Remember seeing Silver companies. HL, MAG, AG SVM, FVI, in short order you will need this information. Keep a copy of this.
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.